ABCB1 genetic variants in leukemias: current insights into treatment outcomes
Open Access
- 1 May 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Pharmacogenomics and Personalized Medicine
- Vol. ume 10, 169-181
- https://doi.org/10.2147/pgpm.s105208
Abstract
ABCB1 genetic variants in leukemias: current insights into treatment outcomes Ravindran Ankathil Human Genome Centre, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia Despite improvements in treatment of different types of leukemia, not all patients respond optimally for a particular treatment. Some treatments will work better for some, while being harmful or ineffective for others. This is due to genetic variation in the form of single-nucleotide polymorphisms (SNPs) that affect gene expression or function and cause inherited interindividual differences in the metabolism and disposition of drugs. Drug transporters are one of the determinants governing the pharmacokinetic profile of chemotherapeutic drugs. The ABCB1 transporter gene transports a wide range of drugs, including drugs used in leukemia treatment. Polymorphisms in the ABCB1 gene do affect intrinsic resistance and pharmacokinetics of several drugs used in leukemia treatment protocols and thereby affect the efficacy of treatment and event-free survival. This review focuses on the impact of three commonly occurring SNPs (1236C>T, 2677G>T/A, and 3435C>T) of ABCB1 on treatment response of various types of leukemia. From the literature available, some of the genotypes and haplotypes of these SNPs have been found to be potential determinants of interindividual variability in drug disposition and pharmacologic response in different types of leukemia. However, due to inconsistencies in the results observed across the studies, additional studies, considering novel genomic methodologies, comprehensive definition of clinical phenotypes, adequate sample size, and uniformity in all the confounding factors, are warranted. Keywords: leukemia, ABCB1 polymorphisms, chemotherapy response, survivalKeywords
This publication has 102 references indexed in Scilit:
- Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem CellsStem Cells International, 2013
- SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid LeukemiaPLOS ONE, 2012
- Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapyHaematologica, 2012
- Genetic variants inCYP(-1A2,-2C9,-2C19,-3A4and-3A5),VKORC1andABCB1genes in a black South African population: a window into diversityPharmacogenomics, 2011
- The P-glycoprotein multidrug transporterEssays in Biochemistry, 2011
- Very important pharmacogene summaryPharmacogenetics and Genomics, 2011
- Impact ofABCB1Allelic Variants on QTc Interval ProlongationClinical Cancer Research, 2011
- The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy numberBlood, 2010
- Ancestry and pharmacogenetics of antileukemic drug toxicityBlood, 2007
- Ethnicity-related polymorphisms and haplotypes in the human ABCB1 genePharmacogenomics, 2007